When the effect of blocking platelet-derived RANKL on tumor cell proliferation/survival was determined, a statistically significant albeit not relevant effect of denosumab was observed as compared to the application of a respective isotype control (p < 0.0001; Wilcoxon signed-rank test). This evidence concerns the gene TNFSF11 and neoplasm.